4-(2,3-dihydro-4H-1,4-benzothiazin-4-ylmethyl)benzoic acid | 503168-32-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 4-(2,3-dihydro-4H-1,4-benzothiazin-4-ylmethyl)benzoic acid
• 英文别名: 4-[(2,3-Dihydro-4H-1,4-benzothiazin-4-yl)methyl]benzoic acid；4-(2,3-dihydro-1,4-benzothiazin-4-ylmethyl)benzoic acid
• CAS: 503168-32-9
• 化学式: C₁₆H₁₅NO₂S
• 分子量: 285.367
• InChiKey: LMWXIYIIETYLQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030139388A1

  公开（公告）日：2003-07-24

  The present application describes novel cyclic hydroxamic acids of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR 1 , and S(O) p , and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.

  本申请描述了新型的公式I:1的环式羟羧酸，或其药用盐形式，其中环B是一个包含0-2个来自O、N、NR1和S(O)p的杂原子以及0-1个羰基的5-7元环系统，其他变量在本说明书中有定义，这些化合物可作为基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶或其组合的抑制剂，包含这些化合物的药物组合物，以及使用这些化合物的方法。
• Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030130273A1

  公开（公告）日：2003-07-10

  The present application describes novel hydantoin derivatives of formula (I): 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 11 , and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.

  本申请描述了具有以下式(I)的新型咪唑啉衍生物：1或其药用可接受的盐或前药形式，其中A、B、R1、R2、R3、R4、R5、R6、R7、R11和n在本说明书中有定义，这些衍生物可用作基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶的抑制剂，或其组合。
• Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030087882A1

  公开（公告）日：2003-05-08

  The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), and/or aggrecanase inhibitors.

  本申请描述了新颖的式I的螺环式&bgr;-氨基酸衍生物或其药用盐形式，其中环B是3-13成员碳环或杂环，环C形成3-11成员的螺环碳环或螺环杂环在环B上，并且其他变量在本规范中定义，这些衍生物可用作基质金属蛋白酶（MMP）、TNF-&agr;转化酶（TACE）和/或聚集素酶抑制剂。
• HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：Bristol-Myers Squibb Company

  公开号：EP1397137B1

  公开（公告）日：2009-10-14
• US6720329B2
  申请人：——

  公开号：US6720329B2

  公开（公告）日：2004-04-13